Evidence map›Paper›PMID 40185871›Full record

ArticleNPJ precision oncology2025

The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer.

Abdul R Farooq, Amy X Zhang, Michelle Chan-Seng-Yue, James T Topham, Grainne M O'Kane, Gun Ho Jang, Sandra Fischer, Anna Dodd, Spring Holter, Julie Wilson and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Abdul R Farooq *Princess Margaret Cancer Centre, Toronto, ON, Canada. ar.farooq@gmail.com.
Amy X Zhang *Ontario Institute for Cancer Research, Toronto, ON, Canada.
Michelle Chan-Seng-Yue *Ontario Institute for Cancer Research, Toronto, ON, Canada.
James T TophamBC Cancer, University of British Columbia, Vancouver, BC, Canada.
Grainne M O'KaneTrinity St. James's Cancer Institute, Dublin, Ireland.ORCID http://orcid.org/0000-0002-8690-403X
Gun Ho JangOntario Institute for Cancer Research, Toronto, ON, Canada.
Sandra FischerUniversity of Toronto, Toronto, ON, Canada.
Anna DoddPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Spring HolterPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Julie WilsonOntario Institute for Cancer Research, Toronto, ON, Canada.ORCID http://orcid.org/0000-0003-2510-962X
Robert C GrantPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Kyaw Lwin AungThe University of Texas at Austin, Austin, TX, USA.
George ZogopoulosMcGill University Health Centre, Montreal, QC, Canada.ORCID http://orcid.org/0000-0002-0482-7086
Elena ElimovaPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Rebecca PrincePrincess Margaret Cancer Centre, Toronto, ON, Canada.
Raymond JangPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Malcolm MoorePrincess Margaret Cancer Centre, Toronto, ON, Canada.
James BiagiCancer Centre of Southeastern Ontario/Queen's University, Kingston, ON, Canada.
Patricia TangDepartment of Oncology, University of Calgary, Calgary, AB, Canada.
Rachel GoodwinDivision of Medical Oncology, Department of Medicine, The Ottawa Hospital, The University of Ottawa, Ottawa, ON, K1N 6N5, Canada.
Oliver F BatheDepartment of Oncology, Tom Baker Cancer Center, University of Calgary, 1331 29th St NW, Calgary, AB, T2N 4N2, Canada.
Marco MarraBC Cancer, University of British Columbia, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0001-7146-7175
Janessa LaskinBC Cancer, University of British Columbia, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0002-0161-9329
Daniel J RenoufBC Cancer, University of British Columbia, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0002-7597-6089
David F SchaefferDepartment of Pathology, Vancouver General Hospital, Vancouver, BC, Canada.
Joanna M KarasinskaBC Cancer, University of British Columbia, Vancouver, BC, Canada.
Faiyaz NottaOntario Institute for Cancer Research, Toronto, ON, Canada.
Steven GallingerOntario Institute for Cancer Research, Toronto, ON, Canada.
Jennifer J KnoxPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Erica S TsangPrincess Margaret Cancer Centre, Toronto, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tandem duplicator phenotype (TDP) consists of distinct genomic rearrangements where tandem duplications are randomly distributed. In this study, we characterized the prevalence and outcomes of TDP in a large series of prospectively sequenced tumors from patients with pancreatic ductal adenocarcinomas (PDAC). Whole-genome sequencing (WGS) was performed in 530 PDAC cases from the PanCuRx Initiative, COMPASS and PanGen/POG trials in Canada. Of 530 cases, 52 were identified as TDP (9.8%; 13 resected, 39 advanced). Etiological subgroups of TDP included BRCA1 (n = 9), CCNE1 (n = 4), and unknown (n = 39). Presence of TDP was not prognostic in resected specimens (p = 0.77) compared with non-HRD and non-TDP cases, described as typicals. In advanced cases, when stratified for only classical subtype cases, platinum therapy was correlated with longer response in non-BRCA1 TDP vs. typicals (p = 0.0036). There was no difference in overall survival between TDP and typicals (p = 0.5).TDP represents a potential novel targetable subgroup for chemotherapy selection in PDAC.

Identifiers

PMID40185871
PMCPMC11971333

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.